Literature DB >> 18559645

Evaluation of Etest method for determining isavuconazole MICs against Cryptococcus gattii and Cryptococcus neoformans.

George R Thompson1, Annette W Fothergill, Nathan P Wiederhold, Ana C Vallor, Brian L Wickes, Thomas F Patterson.   

Abstract

We compared Etest with broth microdilution testing for isavuconazole activity against 92 Cryptococcus isolates. A 97.8% agreement was found between these methods, without major discrepancies (>2-well dilution difference). Our findings support the use of the Etest methodology as a reliable method for the determination of MICs against Cryptococcus spp.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18559645      PMCID： PMC2493144          DOI： 10.1128/AAC.00646-08

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  10 in total

1.  Collaborative comparison of broth macrodilution and microdilution antifungal susceptibility tests.

Authors:  A Espinel-Ingroff; C W Kish; T M Kerkering; R A Fromtling; K Bartizal; J N Galgiani; K Villareal; M A Pfaller; T Gerarden; M G Rinaldi
Journal:  J Clin Microbiol       Date:  1992-12       Impact factor: 5.948

2.  Antifungal susceptibility testing of yeast isolates from blood cultures by microbroth dilution and the E test.

Authors:  A E Simor; G Goswell; L Louie; M Lee; M Louie
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-09       Impact factor: 3.267

3.  Antifungal susceptibility testing using the E test: comparison with the broth macrodilution technique.

Authors:  S C Chen; M L O'Donnell; S Gordon; G L Gilbert
Journal:  J Antimicrob Chemother       Date:  1996-02       Impact factor: 5.790

4.  In vitro activities of isavuconazole and other antifungal agents against Candida bloodstream isolates.

Authors:  H Seifert; U Aurbach; D Stefanik; O Cornely
Journal:  Antimicrob Agents Chemother       Date:  2007-02-16       Impact factor: 5.191

5.  In Vitro activity of the new azole isavuconazole (BAL4815) compared with six other antifungal agents against 162 Cryptococcus neoformans isolates from Cuba.

Authors:  Maria-Teresa Illnait-Zaragozi; Gerardo F Martínez; Ilse Curfs-Breuker; Carlos M Fernández; Teun Boekhout; Jacques F Meis
Journal:  Antimicrob Agents Chemother       Date:  2008-01-22       Impact factor: 5.191

Review 6.  New and emerging treatments for fungal infections.

Authors:  A C Pasqualotto; D W Denning
Journal:  J Antimicrob Chemother       Date:  2008-01       Impact factor: 5.790

7.  Evaluation of Etest method for determining voriconazole and amphotericin B MICs for 162 clinical isolates of Cryptococcus neoformans.

Authors:  M J Maxwell; S A Messer; R J Hollis; D J Diekema; M A Pfaller
Journal:  J Clin Microbiol       Date:  2003-01       Impact factor: 5.948

8.  Single-ascending-dose pharmacokinetics and safety of the novel broad-spectrum antifungal triazole BAL4815 after intravenous infusions (50, 100, and 200 milligrams) and oral administrations (100, 200, and 400 milligrams) of its prodrug, BAL8557, in healthy volunteers.

Authors:  Anne Schmitt-Hoffmann; Brigitte Roos; Markus Heep; Michael Schleimer; Erhard Weidekamm; Tom Brown; Michael Roehrle; Christoph Beglinger
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.938

9.  In vitro activity of a new triazole BAL4815, the active component of BAL8557 (the water-soluble prodrug), against Aspergillus spp.

Authors:  Peter A Warn; Andrew Sharp; David W Denning
Journal:  J Antimicrob Chemother       Date:  2005-11-10       Impact factor: 5.758

10.  In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species.

Authors:  Jesús Guinea; Teresa Peláez; Sandra Recio; Marta Torres-Narbona; Emilio Bouza
Journal:  Antimicrob Agents Chemother       Date:  2008-01-22       Impact factor: 5.938
  10 in total
  14 in total

Review 1.  Isavuconazole: a comprehensive review of spectrum of activity of a new triazole.

Authors:  George R Thompson; Nathan P Wiederhold
Journal:  Mycopathologia       Date:  2010-06-05       Impact factor: 2.574

2.  Comparison of MIC Test Strip and Sensititre YeastOne with the CLSI and EUCAST Broth Microdilution Reference Methods for In Vitro Antifungal Susceptibility Testing of Cryptococcus neoformans.

Authors:  Fatima Zohra Delma; Abdullah M S Al-Hatmi; Jochem B Buil; Hein van der Lee; Marlou Tehupeiory-Kooreman; G Sybren de Hoog; Joseph Meletiadis; Paul E Verweij
Journal:  Antimicrob Agents Chemother       Date:  2020-03-24       Impact factor: 5.191

3.  Isavuconazole Is Effective for the Treatment of Experimental Cryptococcal Meningitis.

Authors:  Nathan P Wiederhold; Laura Kovanda; Laura K Najvar; Rosie Bocanegra; Marcos Olivo; William R Kirkpatrick; Thomas F Patterson
Journal:  Antimicrob Agents Chemother       Date:  2016-08-22       Impact factor: 5.191

4.  The Investigational Fungal Cyp51 Inhibitor VT-1129 Demonstrates Potent In Vitro Activity against Cryptococcus neoformans and Cryptococcus gattii.

Authors:  Shawn R Lockhart; Annette W Fothergill; Naureen Iqbal; Carol B Bolden; Nina T Grossman; Edward P Garvey; Stephen R Brand; William J Hoekstra; Robert J Schotzinger; Elizabeth Ottinger; Thomas F Patterson; Nathan P Wiederhold
Journal:  Antimicrob Agents Chemother       Date:  2016-03-25       Impact factor: 5.191

Review 5.  Cryptococcus gattii infections.

Authors:  Sharon C-A Chen; Wieland Meyer; Tania C Sorrell
Journal:  Clin Microbiol Rev       Date:  2014-10       Impact factor: 26.132

6.  In vitro antifungal activities of isavuconazole and comparators against rare yeast pathogens.

Authors:  Jesús Guinea; Sandra Recio; Pilar Escribano; Teresa Peláez; Beatriz Gama; Emilio Bouza
Journal:  Antimicrob Agents Chemother       Date:  2010-06-21       Impact factor: 5.191

7.  In vitro antifungal susceptibilities and amplified fragment length polymorphism genotyping of a worldwide collection of 350 clinical, veterinary, and environmental Cryptococcus gattii isolates.

Authors:  Ferry Hagen; Maria-Teresa Illnait-Zaragozi; Karen H Bartlett; Daniëlle Swinne; Erik Geertsen; Corné H W Klaassen; Teun Boekhout; Jacques F Meis
Journal:  Antimicrob Agents Chemother       Date:  2010-09-20       Impact factor: 5.191

Review 8.  New Perspectives on Antimicrobial Agents: Isavuconazole.

Authors:  James S Lewis; Nathan P Wiederhold; Morgan Hakki; George R Thompson
Journal:  Antimicrob Agents Chemother       Date:  2022-08-15       Impact factor: 5.938

9.  Pharmacokinetics and pharmacodynamics of a novel triazole, isavuconazole: mathematical modeling, importance of tissue concentrations, and impact of immune status on antifungal effect.

Authors:  Peter A Warn; Andrew Sharp; Arvind Parmar; Jayesh Majithiya; David W Denning; William W Hope
Journal:  Antimicrob Agents Chemother       Date:  2009-05-18       Impact factor: 5.191

10.  Fluconazole Susceptibility in Cryptococcus gattii Is Dependent on the ABC Transporter Pdr11.

Authors:  Mai Lee Yang; John Uhrig; Kiem Vu; Anil Singapuri; Michael Dennis; Angie Gelli; George R Thompson
Journal:  Antimicrob Agents Chemother       Date:  2015-12-07       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.